EA202091003A1 - Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3 - Google Patents

Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3

Info

Publication number
EA202091003A1
EA202091003A1 EA202091003A EA202091003A EA202091003A1 EA 202091003 A1 EA202091003 A1 EA 202091003A1 EA 202091003 A EA202091003 A EA 202091003A EA 202091003 A EA202091003 A EA 202091003A EA 202091003 A1 EA202091003 A1 EA 202091003A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
pyrazolopyrolopyrimidinedione
inhibitors
new
compounds
Prior art date
Application number
EA202091003A
Other languages
English (en)
Inventor
Маркус Коппитц
Хольгер Зибенайхер
Нико Бройер
Элизабет Пок
Андреа Ротгери
Роланд Нойхаус
Оливер Мартин Фишер
Йенс Нагель
Адам Джеймс Дейвенпорт
Джеймс Линдси Карр
Роберт Джеймс Таунсенд
Нина Коннелли Урсиниова
Шелли Энн Пэрротт
Original Assignee
Байер Акциенгезельшафт
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Акциенгезельшафт, Байер Фарма Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Publication of EA202091003A1 publication Critical patent/EA202091003A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение охватывает замещенные производные пиразолопирролопиримидиндиона (PPPD) общей формулы (I)в которой R, Rи Rявляются такими, как определено в настоящем документе, способы получения указанных соединений, фармацевтические композиции и комбинации, содержащие указанные соединения, и применение указанных соединений для производства фармацевтических композиций для лечения или профилактики заболеваний, в частности нейрогенных заболеваний, в виде единственного средства или в комбинации с другими активными компонентами.
EA202091003A 2017-10-27 2018-10-18 Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3 EA202091003A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198769 2017-10-27
PCT/EP2018/078567 WO2019081343A1 (en) 2017-10-27 2018-10-18 NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS

Publications (1)

Publication Number Publication Date
EA202091003A1 true EA202091003A1 (ru) 2020-09-11

Family

ID=60190695

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091003A EA202091003A1 (ru) 2017-10-27 2018-10-18 Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3

Country Status (25)

Country Link
US (1) US11319324B2 (ru)
EP (1) EP3700907B1 (ru)
JP (1) JP7250011B2 (ru)
KR (1) KR20200078567A (ru)
CN (1) CN111527090B (ru)
AU (1) AU2018354777A1 (ru)
BR (1) BR112020008122B1 (ru)
CA (1) CA3080249A1 (ru)
CL (1) CL2020001107A1 (ru)
CO (1) CO2020005065A2 (ru)
CR (1) CR20200174A (ru)
CU (1) CU20200038A7 (ru)
DK (1) DK3700907T3 (ru)
DO (1) DOP2020000100A (ru)
EA (1) EA202091003A1 (ru)
EC (1) ECSP20023626A (ru)
ES (1) ES2914377T3 (ru)
IL (1) IL274036A (ru)
JO (1) JOP20200100A1 (ru)
MA (1) MA50439A (ru)
MX (1) MX2020004981A (ru)
NI (1) NI202000031A (ru)
PH (1) PH12020550494A1 (ru)
SG (1) SG11202003662XA (ru)
WO (1) WO2019081343A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
KR20220113385A (ko) * 2019-12-10 2022-08-12 상하이 한서 바이오메디컬 컴퍼니 리미티드 피라졸-함유 다환식 유도체 억제제, 그의 제조 방법 및 그의 적용
WO2022175514A1 (en) * 2021-02-22 2022-08-25 Bayer Aktiengesellschaft N-(pyridin-2-yl)-acetamides as p2x3 inhibitors
WO2023021328A1 (en) * 2021-08-17 2023-02-23 Bellus Health Cough Inc. Preparation of a p2x3 antagonist

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425541A1 (en) * 1988-07-21 1991-05-08 The Upjohn Company Pyrazolo-azolo-pyrimidine-diones
CA2206080A1 (en) * 1995-09-28 1997-04-03 Otsuka Pharmaceutical Factory, Inc. Analgesic composition_of pryazolo{1,5-a}pyrimidine derivatives
CA2382676A1 (en) 1999-11-05 2001-05-17 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
CN101466714B (zh) 2006-06-23 2013-02-06 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US9260425B2 (en) * 2011-08-12 2016-02-16 Genetech, Inc. Pyrazolo[3,4-c]pyridine compounds and methods of use
WO2013182519A1 (en) * 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
CA2897985A1 (en) * 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CN111527090B (zh) 2023-05-26
CU20200038A7 (es) 2021-03-11
SG11202003662XA (en) 2020-05-28
JP7250011B2 (ja) 2023-03-31
MX2020004981A (es) 2020-08-24
EP3700907B1 (en) 2022-03-09
DOP2020000100A (es) 2020-09-15
MA50439A (fr) 2021-05-19
AU2018354777A1 (en) 2020-04-16
CO2020005065A2 (es) 2020-05-29
CA3080249A1 (en) 2019-05-02
BR112020008122A2 (pt) 2020-11-03
BR112020008122B1 (pt) 2022-11-01
NI202000031A (es) 2020-08-28
CN111527090A (zh) 2020-08-11
DK3700907T3 (da) 2022-05-30
WO2019081343A1 (en) 2019-05-02
PH12020550494A1 (en) 2021-01-11
US11319324B2 (en) 2022-05-03
EP3700907A1 (en) 2020-09-02
ECSP20023626A (es) 2020-06-30
CR20200174A (es) 2020-06-26
JOP20200100A1 (ar) 2020-05-06
CL2020001107A1 (es) 2020-10-23
US20210317128A1 (en) 2021-10-14
IL274036A (en) 2020-06-30
JP2021500380A (ja) 2021-01-07
ES2914377T3 (es) 2022-06-10
KR20200078567A (ko) 2020-07-01

Similar Documents

Publication Publication Date Title
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201792047A1 (ru) Новые соединения
EA201791261A1 (ru) 1,3-тиазол-2-ил замещенные бензамиды
EA201792421A1 (ru) Амидозамещенные производные циклогексана
EA201892666A1 (ru) 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA202090448A1 (ru) Дигидрооксадиазиноны
EA202091003A1 (ru) Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3
EA201691881A1 (ru) Новые соединения
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
EA201691878A1 (ru) ИНГИБИТОРЫ СИГНАЛЬНЫХ ПУТЕЙ Wnt
EA201990947A1 (ru) Замещенные производные 6-(1h-пиразол-1-ил)пиримидин-4-амина и их применение